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Telomerase activity is involved in telomere length maintenance. Leukocytes, unlike
many human somatic tissues, have detectable telomerase activity. These cells provide a
normal human cell type in which to study telomerase. We studied the regulation of
telomerase activity and the telomerase RNA component as leukocytes were stimulated to
enter the cell cycle. In primary human leukocytes stimulated with phytohemagglutinin,
telomerase activity increased >10-fold as naturally quiescent cells entered the cell cycle.
Antibodies to the T cell receptor (TCR)/CD3 complex and the costimulatory CD28
receptor induced telomerase activity in a T cell-enriched population of cells. Rapamycin,
an immunosuppressant that blocks TCR/CD3 signal transduction pathways and cdk2
activation, blocked telomerase induction. Hydroxyurea, an inhibitor of S phase, did not
block cdk2 kinase activity or telomerase activation. In summary, telomerase is regulated
in Gi phase as normal human T cells enter the cell cycle.
INTRODUCTION
In mammals, cell-cycle progression is often regulated
by external signals that are transmitted to a cell
through a variety of well-defined signal transduction
pathways. Understanding the processes that are reg-
ulated by the external signals provides valuable in-
sight into the regulation of cell proliferation. Telomer-
ase activity is tightly regulated during mammalian
development and may be required for the long-term
proliferation of some cell types. To begin to under-
stand the pathways that regulate telomerase in normal
human cells, we studied telomerase activity during
human T cell activation.
Telomerase is a ribonucleoprotein DNA polymerase
that synthesizes telomere repeats onto chromosome
ends (Greider and Blackburn, 1985,1987; Morin, 1989;
Prowse et al., 1993). In most eukaryotes telomere DNA
consists of many tandem repeats of simple sequence
motifs; for example, human telomeres contain -10
kilobase pairs (kbp) of tandem TTAGGG repeats (re-
viewed in Henderson, 1995). The addition of telomere
sequence repeats by telomerase balances telomere
shortening that occurs with each cell division, presum-
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ably caused by the inability of DNA polymerases to
completely replicate the chromosome ends (Watson,
1972; Olovnikov, 1973).
When telomere elongation is compromised in yeast
by deleting telomerase components or other regula-
tors of telomere length, telomeres shorten and cell
viability decreases dramatically (Lundblad and Szos-
tak, 1989; Singer and Gottschling, 1994; McEachern
and Blackburn, 1995). This loss in cell viability is likely
due to chromosome instability. Chromosomes without
telomeres are unstable, lead to rearrangements (Mc-
Clintock, 1941, 1942; reviewed in Greider, 1991) and
chromosome loss (Haber and Thorburn, 1984), and
can signal cell-cycle arrest (Sandell and Zakian, 1993),
presumably because they are recognized as damaged
DNA.
During the growth of immortal single-cell organ-
isms, such as ciliates and yeast, telomere length is
established as an equilibrium between telomere short-
ening and telomere elongation by telomerase (re-
viewed in Greider and Harley, 1996). In mammals,
telomere length and telomerase activity are develop-
mentally regulated. Telomere length varies between
different tissues in adult mice, and these differences
are established during postnatal development
(Prowse and Greider, 1995). The RNA component of
telomerase is present at high levels in newborn mice
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but is specifically down-regulated during postnatal
growth (Blasco et al., 1995). Although many adult hu-
man somatic tissues do not express telomerase, some
adult tissues, such as lymphocytes, do express active
enzyme (Broccoli et al., 1995; Counter et al., 1995;
Hiyama et al., 1995).
Telomerase activity is present in many human tu-
mors and immortal cell lines (reviewed in Harley et al.,
1994; Kim et al., 1994; Bacchetti and Counter, 1995).
Evidence from cultured cell lines suggests that telom-
erase activation may be required for the indefinite
proliferation of immortal cancer cells (Counter et al.,
1992, 1994; Shay et al., 1993). Thus, telomerase inhibi-
tors have been proposed as potential anticancer agents
(reviewed in Harley et al., 1994; Bacchetti and Counter,
1995).
Telomere shortening with aging is observed in a
variety of human cell types, including white blood
cells (Harley et al., 1990; reviewed in Harley, 1995a;
Hastie et al., 1990; Lindsey et al., 1991; Vaziri et al.,
1993). In addition to total leukocyte populations, telo-
mere shortening is seen in hematoroietic progenitor
cells (Vaziri et al., 1994) and in CD4 naive and mem-
ory cells (Weng et al., 1995). In the CD4+ T cells, the
naive cells have longer telomeres than the memory T
cells, and long telomeres correlated with a higher rep-
licative capacity in culture (Weng et al., 1995).
Although normal leukocytes express telomerase ac-
tivity (Broccoli et al., 1995; Counter et al., 1995; Hiyama
et al., 1995), telomere length shortens in leukocytes in
vivo (Vaziri et al., 1993). Telomere shortening during
human aging has also been observed in hematopoietic
progenitor cells (CD34+, CD38-/lo) that express te-
lomerase (Vaziri et al., 1994; Hiyama et al., 1995). Either
the telomerase that is present in these cells is insuffi-
cient to maintain telomeres, or some additional essen-
tial component of telomere length maintenance is ab-
sent in these cells.
Although the identification of telomerase activity in
normal leukocytes raises new considerations for anti-
telomerase cancer therapies, it also provides an oppor-
tunity to study telomerase regulation in a noncancer-
ous cell type. Signal transduction pathways that
regulate leukocyte development and proliferation are
well established. Unstimulated leukocytes isolated di-
rectly from human blood are arrested in the GO phase
of the cell cycle (reviewed in Crabtree, 1989; Ullman et
al., 1990). Cross-linking of cell surface receptors on T
cells by lectins or antibodies initiates a signal trans-
duction cascade that alters gene expression and leads
to entry into the cell cycle and DNA synthesis (Ullman
et al., 1990; Crabtree and Clipstone, 1994). To begin to
understand telomerase regulation in normal human
cells, we analyzed telomerase activity and the telom-
erase RNA component in T cells stimulated to enter
the cell cycle.
MATERIALS AND METHODS
Isolation and Culturing of Leukocytes
Peripheral blood leukocytes were isolated from heparin-treated
blood by density gradient centrifugation in Ficoll and sodium dia-
trizoate solution (Lymphocyte Separation Medium; Boehringer
Mannheim, Indianapolis, IN). Whole blood was layered on the
Ficoll solution and centrifuged for 20 min at 1800 rpm. The gradient
interface, containing peripheral blood mononuclear cells, was col-
lected, and the cells were washed in phosphate-buffered saline
(PBS). The percentage of CD2+ cells (T cells) and CD20+ cells (B
cells) was determined by cell surface staining and flow cytometry
with anti-CD2 antibodies (clone RPA-2.10; Pharmingen, San Diego,
CA) and CD20 antibodies (clone 2H7; Pharmingen). The leukocytes
were typically cultured at 5-10 x 105/ml in RPMI media (Life
Technologies, Gaithersburg, MD) supplemented with 2 mM glu-
tamine and 20% fetal bovine serum (FBS; HyClone, Logan, UT). For
the stimulation/depletion/restimulation experiment, the leuko-
cytes were cultured at 5 x 106 cells/ml from day 0 to day 3. At the
time of addition of the IL-2, the cells were diluted 10-fold in serum-
containing media.
Stimulation and Inhibition of
Leukocyte Proliferation
Phytohemagglutinin (M form; Life Technologies) and interleukin 2
(Lymphocult-T; Biotest, Denville, NJ) were prepared according to
the manufacturer's instructions. Interleukin 2 was added to the
culture medium at a final concentration of 20 U/ml. Rapamycin
(kind gift of the Drug Synthesis and Chemistry Branch, Develop-
mental Therapeutics Program, Division of Cancer Treatment, Na-
tional Cancer Institute, Bethesda, MD) was dissolved in 100% eth-
anol and added to the medium at a final concentration of 0.05-500
nM. Hydroxyurea (Sigma Chemical, St. Louis, MO), dissolved in
sterile distilled water, was added to the medium at a final concen-
tration of 10 mM.
Enrichment for Quiescent T Cells and CD3 and
CD28 Stimulation
A leukocyte fraction enriched for quiescent T cells was prepared as
described (Firpo et al., 1994). Peripheral blood leukocytes from a
Ficoll gradient interface were washed with PBS, pelleted, resus-
pended in 1 ml of 150 mM NaCl and 30% Percoll (Pharmacia,
Piscataway, NJ) solution, and layered onto a discontinuous Percoll
gradient. The gradient contained 2.5 ml of each of the following
Percoll solutions (bottom to top): 60, 55, 50, 45, and 40%. Colored
density beads (Pharmacia) were included in an adjacent gradient as
density markers. After centrifugation at 1500 x g for 20 min, the
dense fraction (including the 55%/60% Percoll interface and 1.5 ml
of the 60% fraction) was removed and diluted to <15% Percoll in
PBS. To deplete B cells, the cells were pelleted, resuspended in
RPMI + 20% FBS, and loaded onto a sterile, nylon wool column in
one void volume. After incubation for 1 h at 37°C, the nonadherent
cells were collected by washing the column with several void vol-
umes of media. Cell number was determined at each step of puri-
fication. From 50 ml of whole blood, 5 x 107 cells were obtained
from the Ficoll interface, 3.3 x 106 cells from the dense fraction of
the Percoll gradient, and 1.5 x 106 cells from the nylon wool
column. The cells were pelleted, resuspended in media, and cul-
tured in the presence of anti-CD3 and anti-CD28 antibodies. The
anti-CD3 antibodies (OKT3 ascites; kind gift of Dr. Dafna Bar Sagi,
State University of New York, Stony Brook) were diluted 1:10 in PBS
and used to coat the wells of a 96-well tissue culture plate by
incubation at 37°C for 1 h, followed by washing with PBS. Anti-
CD28 antibodies were added to the media at a final concentration of
10 ng/ml.
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Cell Lysis and Polymerase Chain Reaction (PCR)-
enhanced Telomerase Assay
Cells (1 x 106) were lysed in 100 ,ul of CHAPS buffer {10 mM
Tris-HCl, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.5% CHAPS (3-
[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate), 10%
glycerol, 5 mM ,B-mercaptoethanol, 1 mg/ml pepstatin, 10 mg/ml
leupeptin, and 0.1 M phenylmethylsulfonyl fluoride}. Insoluble cel-
lular components were removed by centrifugation at 14,000 x g for
10 min. Each extract was divided and incubated in the presence or
absence of DNase-free RNase (1.0 ,ug RNase/20 ,tg total protein) for
15 min at 37°C. Telomerase activity in each extract was measured
with a modified version of the Telomeric Repeat Amplification
Protocol (TRAP; Kim et al., 1994). The modified telomerase assay
was performed as follows: 5 ,ul of cellular extract was mixed with 5
,l of a 2x telomerase reaction mix containing (in mM) 100 Tris
acetate, pH 8.5, 100 potassium acetate, 6 MgCl2, 2 spermine, 2
EGTA, 10 ,B-mercaptoethanol, 4 thymidine triphosphate (dTTP), 4
dATP, 4 2-deoxyguanosine-5'-triphosphate (dGTP), and 2 unla-
beled telomerase substrate (TS) oligonucleotide (Kim et al., 1994).
The TS oligonucleotide served as a substrate for telomerase addition
of deoxynucleotides. The reaction samples were incubated at 30°C
for 60 min. Forty microliters of PCR amplification mix (20 mM
Tris-HCl, pH 8.3, 68 mM KCl, 1.5 mM MgCl2, 1 mM EGTA, 0.5%
Tween, 0.4 mM dCTP, and 20 fM 32P-end labeled TS oligonucleo-
tide) were added to the 10-,ul telomerase reaction. The specific
activity of TS oligonucleotide in the amplification step was 2 x 104
cpm/pmol. To assure "hot start" PCR, the samples were sealed with
wax, and 0.1 ,ug of the second PCR primer (a modified version of the
CX primer [Kim et al., 1994; N. Kim, personal communication]) and
Taq polymerase (2 U) were spotted onto the wax barrier. As a
control for PCR efficiency, 0.1 fmol of a synthetic telomerase product
(TS+5; [5' AATCCGTCGAGCAGAGTTAGGGTTAGGGTTAGGG-
TTAGGTTAG 3']) was added to RNase-treated samples. The sam-
ples were incubated at 94°C for 2 min followed by 18-20 cycles of
PCR (94°C/30 sec, 50°C/30 sec, 72°C/90 sec). Five microliters of the
PCR products were mixed with 5 ,ul of deionized formamide. The
samples were incubated at 90°C for 1 min, and the amplified telom-
erase products were resolved on a 12% acrylamide/7 M urea/0.6 x
trisborate EDTA (TBE) gel.
Telomerase activity was quantified by phosphorimaging. The
signal intensity from each lane of the gel was quantified by defining
a rectangular boundary around all visible bands in the lane with the
most intense signal. A rectangle of equivalent size and shape was
used for quantifying the signal from each lane on a gel. The signal
present in the "no extract" lane was subtracted as background.
Measurement of DNA Content and Percentage of
Cellular Debris by Flow Cytometry
One million cells were resuspended in 500 ,ul of PBS plus 1% calf
serum. Five ml of ethanol (75-95%) were added to fix the cells. The
cells were stored at 4°C overnight (or up to 2 wk) before staining.
For staining, the fixed cells were removed from the ethanol by
centrifugation and resuspended in PBS with 50 ,ug/ml propidium
iodide and 100 ,ug/ml RNase A. After 1 h of incubation at 37°C, the
cells were either stored at 4°C or analyzed immediately by flow
cytometry with an EPICS elite enhanced sorting performance (ESP)
(Coulter Corporation, Hialeah, FL). The percentage of cells in each
phase of the cell cycle was determined by the Multicycle software
program (distributed by Phoenix Flow Systems, San Diego, CA).
The percentage of cellular debris was determined from ungated
histograms with the Multicycle program. This is a measurement of
total debris in the histogram. The percentage of background and
debris (% BAD) was also measured. The % BAD was defined by the
DNA Cytometry Consensus Conference as the proportion of the
histogram events between the leftmost Gl and the rightmost G2 that
is modeled as debris or aggregates. The % BAD is unaffected by
histogram end points. For the samples shown in Figure 3, % BAD
was as follows: phytohemagglutinin (PHA), 5.5%; PHA+IL-2, 2.7%;
PHA+IL-2 depletion, 3.4%; restimulation, 7.1%.
Quantitation of Human Telomerase RNA
Total RNA was prepared from leukocytes cultured for 2 d in PHA
or media alone. The cells were lysed in 0.4 ml of lysis buffer (1.7 M
guanidinium thiocyanate, 10 mM sodium citrate, 90 mM sodium
acetate, 40 mM ,B-mercaptoethanol, 0.4% N-lauroylsarcosine, and
50% water-saturated phenol, pH 4.5) per 106 cells with vortexing.
Two-tenths (0.2) volume of chloroform was added, and the samples
were incubated on ice for 15 min. After centrifugation, the aqueous
phase was removed. The RNA was precipitated by adding an equal
volume of isopropanol. The yield of RNA was 113 and 6 mg from
1.7 x 107 PHA-stimulated and 3.1 X 107 unstimulated cells, respec-
tively.
Total RNA (1 or 5 ,ug) was loaded per lane on a 6% acrylamide/7
M urea/0.6x TBE gel. After electrophoresis, the RNA was trans-
ferred to nylon membrane (Hybond N+; Amersham, Arlington
Heights, IL) by electroblotting in Ix TBE. The RNA was cross-
linked to the filter with 120 mJ UV light in a Stratalinker (Stratagene,
La Jolla, CA). The filter was prehybridized in 200 mM sodium
phosphate, pH 7.2, 15% formamide, 1 mM EDTA, 7% SDS, and 10
mg/ml bovine serum albumin (BSA). Probes for the human telom-
erase RNA and 5S RNA were added simultaneously to the prehy-
bridization mixture. The human telomerase RNA (hTR) antisense
riboprobe was generated by in vitro transcription of the hTR gene
cloned behind the SP6 promoter in the pGEM-5Zf vector. The
specific activity of the hTR probe was 1.6 x 105 cpm/fmol. The 5S
RNA probe was generated by random hexamer labeling of a 170 bp
PCR fragment encompassing the 5S gene (PCR primers 5'GCACG-
GCCGGCCGGGCTG3' and 5'AAGCCTACAGCACCCGG3'). The
specific activity of the 5S RNA probe was 5 x 104 cpm/fmol.
Immunoprecipitation, Kinase Assay, and Western
For immunoprecipitations and immunoblotting, the cells were lysed
in NP40 buffer (50 mM HEPES, pH 7.0, 50 mM NaCl, 0.1% NP40, 1
mM phenylmethylsulfonyl fluoride, 1 ,ug/ml leupeptin, 1 ,tg/ml
pepstatin, and 5 mM dithiothreitol), and insoluble debris was re-
moved by centrifugation at 14,000 x g for 10 min. For immunopre-
cipitation and kinase assays, the lysates were used immediately and
were not frozen, because this results in decreased kinase activity.
Before immunoblotting, lysates were stored at -80°C. Immunopre-
cipitations and immunoblotting were performed as described in
Buchkovich and Ziff (1994). For immunoprecipitations, extracts con-
taining 70 Ag of total protein, as determined by Bio-Rad Protein
Concentration Assay, were used. Anti-Cdk2 polyclonal antibody (5
,ug; Upstate Biotechnology, Lake Placid, NY) or polyclonal rabbit
anti-mouse antibody (Upstate Biotechnology) was added to each
sample. For immunoblotting, extracts containing 50 ,ug of protein
were loaded. The same blot was probed with 2 Ag/ml anti-cdk2
polyclonal antibody (Upstate Biotechnology), 2 ,tg/ml anti-cyclin E
(clone HE12; Pharmingen), and 1:1000 dilution of anti-p27Kip1 anti-
sera (kind gift of Hui Zhang, Cold Spring Harbor Laboratory, NY),
followed by HRP-conjugated goat anti-rabbit (Sigma) or HRP-con-
jugated rabbit anti-mouse (Cappel). The HRP activity was detected
by an enhanced chemiluminescent substrate system (SuperSignal;
Pierce Chemical, Rockford, IL). The blot was stripped of antibodies
for sequential probing by incubation in 2% SDS, 62.5 mM Tris, pH
6.8, and 100 mM 13-mercaptoethanol for 20 min at 65°C.
For kinase assays, immune complexes were washed with kinase
buffer containing (in mM) 20 Tris, pH 7.5, 30 NaCl, 10 MgCl2, and
1.0 dithiothreitol and then incubated in a 50 ,ul reaction containing
kinase buffer (1 x), 20 ,uM ATP, 5 ,uCi y-32P-ATP (6000 Ci per mmol),
and 50 ,ug/ml histone HI (Boehringer Mannheim). The reactions
were stopped by the addition of 2x Laemmli sample buffer. Histone
HI was separated from free y-32P-ATP on 10% polyacrylamide gel.
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RESULTS
Human peripheral blood leukocytes were isolated
from whole blood by density centrifugation in Ficoll.
To determine the percentage of T cells and B cells, the
leukocytes were analyzed for cell surface markers by
antibody staining and flow cytometry. In a typical
experiment 65% of the leukocytes were T cells (CD2+),
and 5% were B cells (CD20+). A large percentage of
the remaining cells were monocytes, based on the
scattering properties of the unstained cells during
flow cytometry.
The leukocytes were treated with PHA, which binds
to the TCR/CD3 complex on T cells (Kanellopoulos et
al., 1985). In a mixed leukocyte population from pe-
ripheral blood, PHA stimulation is sufficient to cause
T cell proliferation (Meuer and Meyer zum Bueschen-
feld, 1986). After 2 d of PHA treatment, >30% of the
leukocytes left the GO phase and entered S phase
(Figure 1). The levels of telomerase activity in extracts
from the untreated and PHA-treated cells were com-
pared (Figure 1). Telomerase activity was measured
with a PCR-enhanced telomerase assay in which the
enzyme was assayed under optimal conditions
(Morin, 1989), and reaction products were amplified
by PCR. A minimal number of PCR amplification
cycles was used to minimize the possibility of PCR-
generated artifacts and to insure quantitative results
(see MATERIALS AND METHODS). In extracts from
the untreated leukocytes, telomerase activity was not
detected (Figure 1). In extracts from cells treated for
1 d with PHA, a low level of activity just above the
lower limit of detection of the assay was observed.
From day 1 to day 2 there was a >10-fold increase in
activity as quantified by phosphorimaging (see MA-
TERIALS AND METHODS), and the level of activity
remained high in extracts from cells treated for 3 d
with PHA. The timing of the increase in telomerase
activity correlated with the increase in the percentage
of cells in S phase.
To verify that the telomerase activity assayed in the
heterogeneous population of leukocytes after PHA
treatment resulted from T cells, we tested the ability of
antibodies specific for the TCR/CD3 complex to up-
regulate telomerase activity in a T cell-enriched frac-
tion of leukocytes. In the absence of antigen-present-
ing cells, maximal stimulation of interleukin 2 (IL-2)
expression and T cell proliferation requires TCR/CD3
signaling along with a costimulatory signaling path-
way (Schwartz, 1992; Shahinian et al., 1993). Thus, we
expected that, if the increase in telomerase activity
results from T cells and is dependent on IL-2 expres-
sion, both TCR/CD3 and CD28 signaling would be
required for maximal telomerase expression.
We isolated a T cell-enriched fraction of leukocytes
(Firpo et al., 1994) and cultured the cells in the pres-
ence of anti-TCR/CD3 and/or anti-CD28 antibodies.
After 2 d of culturing in the presence of one or both
antibodies, the cells were harvested and analyzed for
telomerase activity (Figure 2). Telomerase activity was
not observed in the control (media alone), anti-TCR/
CD3, or anti-CD28 samples. However, telomerase ac-
tivity was detected in the sample treated with both
Go/Gi:S:G2/M 99:11 91:1:8 59:34:8 63:30:8 Figure1. PHAtreatmentof
PHA (days) 0 1 2 3 peripheral blood leukocytes
ledto telom
IIH erase activity and an in-
2cs-c- w_CZ 3 crease in the percentage of¢z O z :_ O z Z o cells inS phase. Freshly iso-
lated leukocytes (day 0) or
leukocytes cultured in the
presence of phytohemagglu-
* tinin (PHA) for 1, 2, or3d
were assayed for cell-cycle
phase distribution and te-5
__ _
lomerase activity. Cell-cycle
5L 5* - * _ phase distribution (the per-
E^ s _ s _ centage of cells in GO/GlSm--- * L -TS+6 phase, S phase, and G2/M
4 - -TS+5 phase) was determined bypropidium iodide staining
and flow cytometry. Telom-
erase activity was analyzed
with a PCR-enhanced telom-
erase assay at three protein
concentrations: 5.0, 2.5, and
1.3 ,ug of total protein per reaction. RNase treatment of each extract (at the highest protein concentration) before the telomerase assay verified
that the assay measured an RNase-sensitive activity. The addition of a synthetic telomerase product, the oligonucleotide TS+5, to each
RNase-treated extract before PCR amplification served as a control for PCR efficiency (control). Extract was omitted from one reaction sample
to control for extract-independent activity (no extract). A 32P-labeled synthetic telomerase product (TS+5) equivalent in base composition and
sequence to the TS oligonucleotide plus [TTAGGG]5, served as a molecular weight marker and comigrated with the smallest product
observed in the TRAP assay.
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Figure 2. Treatment of leukocytes with antibodies specific for CD3
and CD28 resulted in an increase in telomerase activity. A T cell-
enriched fraction of leukocytes was cultured for 2 d in the presence
of only CD3 antibodies, only CD28 antibodies, both CD3 and CD28
antibodies, or media alone. The cells were lysed and assayed for
telomerase activity at two protein concentrations (2.0 and 0.4 ,tg per
reaction). Assay controls for PCR efficiency (control) and RNase-
sensitivity (RNase) were included.
anti-TCR/CD3 and anti-CD28. Thus, telomerase was
activated by the T cell-specific TCR/CD3 and CD28
signaling pathways. In this experiment, telomerase
activation required both TCR/CD3 signaling and
CD28 signaling (Figure 2). In a second experiment, a
low level of telomerase activity was detected with
anti-TCR/CD3 alone, no activity was detected with
anti-CD28 alone, and a high level of activity was de-
tected with anti-TCR/CD3 and anti-CD28 in combina-
tion (our unpublished results). In both experiments,
maximal telomerase activation required both TCR/
CD3 and CD28 signaling, as does maximal IL-2 ex-
pression and proliferation in T cells (Schwartz, 1992;
Shahinian et al., 1993). The requirement for both TCR/
CD3 and CD28 signaling to achieve maximal telomer-
ase activity is consistent with telomerase induction
being downstream of IL-2 signaling. The timing of the
increase in telomerase activity after PHA treatment of
leukocytes (Figure 1) suggested that telomerase acti-
vation was a later event than IL-2 and IL-2Ra expres-
sion (Ullman et al., 1990).
To further examine the correlation between cell cy-
cling and telomerase activation, PHA-treated cells
were treated with exogenous IL-2 at a concentration
that would accelerate cell cycling, the IL-2 and PHA
were then depleted to induce proliferative arrest, and
the cells were restimulated with PHA. During this
regimen of PHA and IL-2 stimulation, depletion, and
restimulation (Figure 3A), telomerase activity and the
percentage of cells in S phase were assayed. Cell num-
ber as an indicator of population doubling rates and
Figure 3. Telomerase activity varied
with the proliferative state of leukocytes
during PHA and IL-2 stimulation, deple-
tion, and restimulation. (A) A timeline
summarizing the culturing conditions
and sampling time points. Leukocytes
were cultured in the presence of PHA for
3 d (PHA) or in PHA for 3 d followed by
IL-2 for 1 d (PHA+IL-2). The PHA was
diluted 10-fold on day 3 at the time of
IL-2 addition. The cell population dou-
bled three times during the 24-h period
after IL-2 addition. Neither PHA nor
IL-2 was added to the media during
days 4-8 (PHA/IL-2 depletion); the cell
population doubled only once during
this time period. PHA was added to the
culture again on day 9 (PHA restimula-
tion). Cellular debris as an indicator of
cell death was monitored by flow cytom-
etry. Percentage of cellular debris: PHA,
11%; PHA+IL-2, 6%; depletion, 19%; re-
stimulation, 18%. (B) At each time point
(days 3, 4, 8, and 10), a sample of leuko-
cytes was removed from the culture and
assayed for cell-cycle phase distribution
and telomerase activity. Telomerase ac-
tivity was analyzed with a PCR-en-
hanced telomerase assay at three protein
concentrations: 2.5, 1.3, and 0.6 ,ug of
total protein per reaction. Controls for
RNase sensitivity (RNase) and PCR effi-
ciency (control) were included.
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cellular debris as an indicator of cell death were also
monitored. Cells treated with PHA for 3 d had detect-
able telomerase activity (Figures 1 and 3B). After the
initial 3 d of PHA treatment, cells were treated with
IL-2. The cells divided rapidly after IL-2 addition,
resulting in three population doublings in 1 d of treat-
ment, an increase in the percentage of cells in S phase,
and an increase in telomerase activity (Figure 3, A and
B). During the next 4 d, IL-2 and PHA were not
replenished in the culture, and the population dou-
bling rate declined with only one doubling occurring
from day 5 to day 8. By day 8 of the experiment, 98%
of the cell population was in GO/Gi phase, and telom-
erase activity was no longer detected. Restimulation of
the cells with PHA resulted in a modest increase in S
phase cells and an increase in telomerase activity (Fig-
ure 3A). The magnitude of this increase cannot be
compared directly with that seen after PHA stimula-
tion of day 0 leukocytes, because the cellular compo-
sition of the population, the activation and differenti-
ation state of the T cells, and the length of PHA
treatment are different. This stimulation, depletion,
and restimulation experiment demonstrated a correla-
tion between cell-cycle entry and telomerase activa-
tion, as well as a correlation between cell-cycle exit
and the down-regulation of telomerase activity. In
addition, the superinduction of telomerase within 1 d
of IL-2 treatment demonstrated telomerase regulation
by IL-2 signaling pathways.
To determine whether the absence of telomerase
activity in untreated leukocytes was due to the pres-
ence of an inhibitor of telomerase activity, telomerase-
negative (day 0) and telomerase-positive (PHA, day 2)
extracts were mixed at different concentrations (Figure
4). An equal amount or up to a ten-fold excess of
telomerase-negative extract did not inhibit the activity
in telomerase-positive extracts, although some de-
crease in the longest products was seen. We conclude
that the telomerase-negative extracts did not contain a
diffusible inhibitor of telomerase activity.
To investigate whether the level of the RNA com-
ponent of telomerase (human telomerase RNA or hTR;
Feng et al., 1995) was regulated in leukocytes, we
performed Northern analysis. RNA was isolated from
leukocytes that were cultured in the absence or pres-
ence of PHA for 2 d. As a positive control, RNA was
also isolated from a telomerase-positive (Prowse et al.,
1993), immortal T cell leukemia cell line, Jurkats. The
steady-state levels of hTR relative to 5S RNA in-
creased after 2 d of PHA stimulation (Figure 5), par-
alleling the increase in telomerase activity in these
cells (Figure 1).
To investigate telomerase regulation in the path-
way(s) downstream of IL-2 receptor and relative to
cell-cycle progression, we blocked T cell proliferation
with the immunosuppressive drug rapamycin. Rapa-
mycin blocks antigen-induced T cell proliferation
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z
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Figure 4. Extracts from quiescent leukocytes did not inhibit telom-
erase activity in extracts from PHA-treated leukocytes. A telomer-
ase-negative extract (2, 10, or 20 ,ug, lanes 3-5) from untreated
leukocytes (day 0, Figure 1) was mixed with 2 ,ug of a telomerase-
positive extract (day 2, Figure 1) before assaying telomerase activity.
The telomerase-positive extract was also assayed in the absence of
the telomerase-negative extract (lane 2), in the presence of 10 ,ug of
BSA (lane 6), or after RNase treatment (lane 1). The day 0 extract did
not inhibit the telomerase activity in the day 2 extract, although
some decrease in the longest products was observed.
downstream of IL-2 receptor and other growth factor
receptors including IL-4 and IL-6 (reviewed in Sigal
and Dumont, 1992; Morice et al., 1993). Rapamycin
inhibits the elimination of p27K'Pl, an inhibitor of cy-
clin-dependent kinases, and blocks the activation of
the cyclin-dependent kinase 2 (cdk2), a kinase re-
quired for the Gl-to-S phase transition (Nourse et al.,
1994). Rapamycin, however, does not block some
other IL-2-mediated activities, such as the enhance-
ment of cytolytic function in cytotoxic T cells (Morice
et al., 1993). We tested the ability of rapamycin to
inhibit telomerase after PHA and IL-2 treatment.
Freshly isolated quiescent leukocytes were treated
with PHA and IL-2 in the presence of 5 or 50 nM
rapamycin. The cells were harvested 2 d later and
analyzed for cell-cycle phase distribution and telom-
erase activity (Figure 6). PHA and IL-2 treatment for
2 d resulted in an increase in S phase cells. Rapamycin
treatment blocked both the increase in telomerase ac-
tivity and the increase in S phase cells to control levels
(Figure 6A). The effect of rapamycin over a broader
concentration range, 0.05-500 nM, was determined
(Figure 6B). Again, rapamycin inhibited both S phase
and telomerase activity.
Rapamycin blocks cells in a Gl-phase-like state
(Firpo et al., 1994; Nourse et al., 1994). To determine
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Leukocytes were treated for 2 d with PHA and
IL-2 in the presence of rapamycin or hydroxyurea.
The cells were lysed, and extracts were assayed for
cdk2 kinase activity in vitro and for steady-state
protein levels of cdk2, cyclin E, and p27KiP1 by West-
ern blotting. In agreement with published results
(Nourse et al., 1994), rapamycin-blocked cells had
high cyclin E protein levels, low cdk2 kinase activ-
ity, and high p27KiPl protein levels (Figure 8). Hy-
droxyurea-treated cells expressed high levels of cy-
clin E protein, high cdk2 kinase activity, and low
p27KiPl protein levels (Figure 8). These results are
consistent with rapamycin inhibiting cells in Gl
phase and hydroxyurea blocking cells in early S
phase, indicating that telomerase is activated in Gi
phase as T cells enter the cell cycle.
-
134
5S- A* __1
Figure 5. The steady-state level of the human telomerase RNA
(hTR) increased after PHA treatment. Total RNA was isolated from
leukocytes grown in the absence or presence of PHA for 2 d and
from Jurkat cells, a human T cell leukemia line. Total RNA (1 and 5
jig) was run on a 6% acrylamide/7 M urea/0.6X TBE gel, trans-
ferred to nylon membrane, and probed with 32P-labeled hTR anti-
sense riboprobe and 32P-labeled 5S RNA probe.
whether an inhibitor of DNA synthesis would have
the same effect on telomerase activity, we treated
leukocytes with hydroxyurea. Although hydroxyu-
rea did inhibit S phase progression, the induction of
telomerase activity was not blocked (Figure 6C).
This demonstrated that telomerase induction oc-
curred independently of DNA synthesis.
To rule out the possibility that rapamycin directly
inhibited telomerase activity, rapamycin was added to
a telomerase assay in vitro. Hydroxyurea was also
tested for inhibition of telomerase in vitro. At concen-
trations equivalent to or 10-fold greater than those
used in the leukocyte culture medium, neither rapa-
mycin nor hydroxyurea inhibited telomerase activity
in vitro (Figure 7). Thus, the effect of rapamycin on
telomerase in vivo is likely to result from the inhibi-
tion of IL-2 signaling and of cell-cycle progression.
To examine the cell-cycle phase of the rapamycin-
and hydroxyurea-blocked leukocytes, we used the cy-
clin-de1pendent kinase 2 (cdk2), cyclin E, and the
p27K'P4 cdk inhibitor as molecular indicators of cell-
cycle phase progression. Cyclin E expression and cdk2
kinase activity increase gradually in Gl phase and are
required for the Gl-to-S phase transition (Pagano et al.,
1993; Tsai et al., 1993; van den Heuvel and Harlow,
1993; Ohtsubo et al., 1995); p27K'Pl is expressed at high
levels in quiescent T cells but at low levels in expo-
nentially proliferating T cells (Nourse et al., 1994).
DISCUSSION
Although telomerase is not expressed in many somatic
tissues, it is expressed in peripheral blood leukocytes
(Broccoli et al., 1995; Counter et al., 1995; Hiyama et al.,
1995). These cells provided a normal human cell type
in which to study telomerase regulation. PHA treat-
ment of peripheral blood leukocytes (Figure 1;
Hiyama et al., 1995) or antibody activation of TCR/
CD3 and CD28 receptors (Figure 2) resulted in an
increase in telomerase activity. Thus, the T cell recep-
tor and CD28 costimulatory pathways are linked to
telomerase activation. Telomerase induction after TCR
engagement correlated with the progression of T lym-
phocytes from Gl into S phase.
The signaling events downstream of TCR/CD3
complex that signal the entry into S phase have been
well studied. Signals generated from the TCR estab-
lish an autocrine signaling pathway involving IL-2
and IL-2 receptor (IL-2R; Ullman et al., 1990; Crabtree
and Clipstone, 1994). Signals from the IL-2R commit
the cell to a program of DNA synthesis by communi-
cating with components of the cell-cycle machinery.
The signaling pathway is blocked by the immunosup-
pressant rapamycin, which blocks the phosphoryla-
tion of the retinoblastoma protein (RB), the expression
of cyclin A and PCNA, the down-regulation ofp271TP11, and the activation of p33cdk2 (reviewed in
Chou and Blenis, 1995). We found that rapamycin
blocked the induction of telomerase, whereas hy-
droxyurea did not, indicating that telomerase is regu-
lated in Gl phase. The inability of hydroxyurea to
block telomerase activation indicated that telomerase
is induced before DNA synthesis and that DNA syn-
thesis itself is not required for telomerase induction.
The increase in telomerase activity after PHA
stimulation was accompanied by an increase in the
level of the telomerase RNA component. Because
the levels of the telomerase RNA component (Figure
4) and telomerase activity (Buchkovich and Greider,
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Figure 6. (A) Rapamycin inhibited the PHA-in-
- TS+6 duced increase in telomerase activity. Leukocytes
TS+5 were cultured for 2 d in media alone; PHA and IL-2;
TS+5 PHA, IL-2, and 5 nM rapamycin; or PHA, IL-2, and
50 nM rapamycin. The cells were harvested and
assayed for phase distribution by propidium iodide
staining and flow cytometry and for telomerase ac-
tivity with a PCR-enhanced telomerase assay at two
protein concentrations (2.5 and 0.5 ,tg of total pro-
tein per reaction). Controls for RNase sensitivity
(RNase) and PCR efficiency (control) were included.
(B) Cells were cultured as in A, except that rapamy-
cin was added at a final concentration of 0.05, 0.5,
5.0, 50, or 500 nM to the media. Telomerase activity
was assayed at 2.0 ,ug of total protein extract per
reaction (5). Telomerase activity in PHA and IL-2-
treated cell extracts was quantitated on a BAS2000
and expressed as arbitrary units (a.u.). The percent-
age of cells in S phase (K) was determined by pro-
pidium iodide staining and flow cytometry. (C) Hy-
droxyurea did not inhibit the PHA-induced increase
in telomerase activity. Leukocytes were cultured for
2 d in media alone, PHA, or PHA and 10 mM hy-
-TS+6 droxyurea. The cells were harvested and assayed for
- TS+5 cell-cycle phase distribution and telomerase activity.
Telomerase activity was measured at two protein
concentrations (5.0 and 0.5 ,tg of total protein per
reaction). Controls for PCR efficiency (control; lanes
1, 5, and 9), RNase sensitivity (RNase; lanes 2, 6, and
10), and extract-independent activity (no extract;
lane 13) were included.
unpublished results) were similar to those found in
the homogeneous population of Jurkat cells. It is
unlikely that only a small subset of the T cells in the
leukocyte population was expressing telomerase.
Telomerase induction during T cell activation could
be regulated by mechanisms affecting the synthesis,
processing, and assembly of telomerase compo-
nents. Although mixing telomerase-negative ex-
tracts with telomerase-positive extracts did not in-
hibit telomerase, indicating there was not a
diffusible telomerase inhibitor, regulation by a tight-
ly-bound specific inhibitor is not excluded.
Although we observed a correlation between de-
creased telomerase activity and cell cycle exit, it is not
yet clear to what extent these activities are linked in T
cells and other cells. When immortal BALB/c3T3 cells
were shifted from active growth to quiescence by ei-
ther serum starvation or contact inhibition, the cells
arrested in GO after 24 h, yet telomerase activity re-
mained constant relative to the levels in the cycling
populations (Buchkovich and Greider, unpublished
results). When similar immortal fibroblast populations
were held quiescent only after 7-13 d, some decrease
in telomerase activity was seen (Holt et al., 1996). This
suggests that telomerase activity is not tightly regu-
lated with cell-cycle exit in immortal mouse fibroblast
lines, or that the enzyme has a long half-life.
Differentiation in vitro of a variety of immortal
cell types leads to low or undetectable telomerase
activity (Sharma et al., 1995; Holt et al., 1996). The
decline in telomerase activity was apparently slower
than the decline of cell-cycle-associated activities in
some cases. Whereas 2 d of retinoic acid treatment
of HL60 cells is sufficient for the accumulation of
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Figure 8. Rapamycin blocked cell cycling in Gl phase, whereas
hydroxyurea blocked the cells at the start of S phase. Leukocytes
were cultured for 2 d in media alone (lane 2); PHA and IL-2 (lanes
1 and 3); PHA, IL-2, and 50 nM rapamycin (lane 4); or PHA, IL-2,
and 10 mM hydroxyurea (lane 5). The cells were lysed in NP40
buffer, assayed for cyclin-dependent kinase-2 (cdk2) activity in
vitro, and the steady-state protein level of cdk2, cyclin E, and the
cdk inhibitor p27KiPl by Western blotting. The immunoprecipita-
tions before the kinase assay were performed with a polyclonal cdk2
antibody (top panel, lanes 2-5) or, as a control, a polyclonal rabbit
anti-mouse IgG (top panel, lane 1). Histone HI served as the sub-
strate in the in vitro kinase reaction.
manner. Whether this lack of regulation is due to a
relaxed control in immortal cell clones or is also found
in normal human cells remains to be demonstrated.
The identification of telomerase regulation in nor-
mal human T cells by the TCR pathway demon-
strates that mature T cells have telomerase activity.
Previous experiments with unstimulated leukocytes
showed low levels of telomerase activity in both
mixed cell population (Counter et al., 1995) and in
fractionated samples containing specific cell types
(Broccoli et al., 1995). This activity may be attributed
to the presence of progenitor stem cells in the pop-
ulation (Counter et al., 1995; Harley, 1995b; Shay
and Wright, 1996). However, peripheral blood T
cells responding to TCR agonists are not progenitor
hematopoietic cells but, rather, mature T cells that
have survived thymic selection (Crabtree, 1989). The
finding that telomerase is expressed in these cells is
significant, because earlier data suggested that only
- TS+6
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Figure 7. Neither rapamycin nor hydroxyurea inhibited telomer-
ase activity in vitro. An extract from PHA-treated leukocytes was
assayed for telomerase activity at two protein concentrations: 0.5 jig
per reaction (lane 3) or 2.5 ,g per reaction (lanes 1-2 and 4-12).
Rapamycin (50,500, or 5000 nM), hydroxyurea (1, 10, or 100 mM), or
the solvents used to dissolve rapamycin and hydroxyurea (ethanol
and water, respectively) were added to the leukocyte extract before
the telomerase assay. Assay controls for PCR efficiency (control; lane
1), RNase-sensitivity (RNase; lane 2), and extract-independent ac-
tivity (no extract; lane 13) were included.
dephosphorylated retinoblastoma protein, a marker
of GO/Gl phase cells (Mihara et al., 1989), 3 d of
retinoic acid treatment is insufficient for the down-
regulation of telomerase activity (Sharma et al.,
1995). Whereas changes in E2F complexes are obvi-
ous by 5 d of retinoic acid treatment in F9 cells (La
Thangue and Rigby, 1987), telomerase activity did
not decrease even after 6 d (Sharma et al., 1995). The
long periods of time required to see reduction in
telomerase in these systems again suggests that ei-
ther telomerase activity has a long half-life or that
the enzyme is not tightly regulated with cell-cycle
exit in these cells.
The T cell experiments described in this paper ad-
dressed only the decisions to enter and exit the cell
cycle, not the continued progression of cycling cells
into each stage of the cell cycle. Phase-specific cell-
cycle regulation of telomerase activity was not de-
tected in HeLa (Avilion, 1995) or in two other immor-
tal cell types, HT1080 or HL60 cells (Holt et al., 1996).
In all three cases, similar levels of activity were de-
tected in cells in the Gl, S, and G2/M phases of the cell
cycle. Thus, the evidence to date suggests that telom-
erase activity is not regulated in a phase-dependent
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germline tissues, stem cells, and fetal tissues ex-
pressed telomerase.
The identification of telomerase activation in ma-
ture T cells raises questions as to the role of telom-
erase in these cells. Telomere shortening with aging
has been observed in total leukocyte populations, in
hematopoietic progenitor cells, and in CD4+ naive
and memory cells (Hastie et al., 1990; Lindsey et al.,
1991; Vaziri et al., 1993, 1994; Weng et al., 1995).
Although telomere shortening in many primary cell
types in vitro has been interpreted as an indicator of
the absence of telomerase (Harley, 1990; reviewed in
Harley, 1991; Hastie et al., 1990; Lindsey et al., 1991),
this may not always be the case. Telomeres shorten
with age in hematopoietic progenitor cells (CD34+
CD38 10o), yet telomerase activity is present (Vaziri
et al., 1994; Hiyama et al., 1995). These data and our
finding of telomerase activity in mature T cells sug-
gest that the ability to express telomerase may not
always lead to telomere length maintenance. There
are large numbers of factors that are involved in
maintaining telomere length, including telomerase,
telomerase regulators, telomere binding proteins,
and possibly telomere processing activities (re-
viewed in Greider, 1996). If some of these other
factors are limiting in human T cells, the expression
of telomerase will not be sufficient to maintain telo-
mere length. An example of this is seen in the yeast
estl mutant, which fails to maintain telomere length
although the cells have levels of telomerase activity
indistinguishable from wild-type cells (Lundblad
and Szostak, 1989; Cohn and Blackburn, 1995). To
understand the role of telomerase in mammalian
somatic cells, it is essential to know whether or not
telomerase is required in normal cells, such as T
cells, that express it.
Normal peripheral blood T cells represent a highly
specialized cell type that is poised in response to ex-
ternal signals to multiply or halt proliferation. The
activation of telomerase seems to be keyed into the
proliferative response pathways in this specialized cell
type. The regulation of telomerase activity during the
cycling of other human cells must be investigated
more carefully to determine whether the regulation of
telomerase with cell cycle entrance and exit is a com-
mon occurrence or unique to lymphocytes. Telomer-
ase induction by TCR is the first example of a signal-
ing pathway in normal cells that regulates telomerase.
This opens the way for experimental analysis of "up-
stream" regulators. Mutations in signaling molecules
that regulate telomerase in normal cells may be re-
sponsible for deregulated telomerase expression in
tumor cells.
Note added in proof. In recent publications, Igarashi and Sakaguchi
(1996) and Weng et al. (1996) also observed telomerase induction
after stimulation of the T cell antigen receptor.
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